These results demonstrate that TNFAIP3 is not required for iFGFR1-mediated ERK1/2 activation, but it is essential for iFGFR1-induced DCIS-iFGFR1 tumor growth and progression in vivo. This evidence concerns the gene MAPK3 and ductal breast carcinoma in situ.